We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Shire, Teva Call Truce In Fight Over Generic ADHD Drug

Law360, New York (May 31, 2013, 7:33 PM EDT) -- A Shire PLC unit said Friday that it had reached a settlement with Teva Pharmaceuticals USA Inc. resolving allegations that Teva infringed two patents for the attention deficit hyperactivity disorder drug Intuniv.

The deal granted Teva — which the suit accused of infringing the patents by seeking U.S. Food and Drug Administration approval of its generic version of the drug — a license to market either its own form of Intuniv or authorized generics made by Shire as of 2015.

Shire sued Teva in Delaware federal court in April 2010, alleging that Teva's ANDA for its generic infringed two patents for...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS